These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 10677527)

  • 1. Regulated expression of P210 Bcr-Abl during embryonic stem cell differentiation stimulates multipotential progenitor expansion and myeloid cell fate.
    Era T; Witte ON
    Proc Natl Acad Sci U S A; 2000 Feb; 97(4):1737-42. PubMed ID: 10677527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bcr-Abl is a "molecular switch" for the decision for growth and differentiation in hematopoietic stem cells.
    Era T
    Int J Hematol; 2002 Jul; 76(1):35-43. PubMed ID: 12138893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p210 Bcr-Abl expression in a primitive multipotent haematopoietic cell line models the development of chronic myeloid leukaemia.
    Pierce A; Owen-Lynch PJ; Spooncer E; Dexter TM; Whetton AD
    Oncogene; 1998 Aug; 17(5):667-72. PubMed ID: 9704934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity.
    Li S; Ilaria RL; Million RP; Daley GQ; Van Etten RA
    J Exp Med; 1999 May; 189(9):1399-412. PubMed ID: 10224280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bcr-Abl has a greater intrinsic capacity than v-Abl to induce the neoplastic expansion of myeloid cells.
    Gross AW; Ren R
    Oncogene; 2000 Dec; 19(54):6286-96. PubMed ID: 11175343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BCR-ABL gene rearrangement and expression of primitive hematopoietic progenitors in chronic myeloid leukemia.
    Bedi A; Zehnbauer BA; Collector MI; Barber JP; Zicha MS; Sharkis SJ; Jones RJ
    Blood; 1993 Jun; 81(11):2898-902. PubMed ID: 8499629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Constitutive and specific activation of STAT3 by BCR-ABL in embryonic stem cells.
    Coppo P; Dusanter-Fourt I; Millot G; Nogueira MM; Dugray A; Bonnet ML; Mitjavila-Garcia MT; Le Pesteur D; Guilhot F; Vainchenker W; Sainteny F; Turhan AG
    Oncogene; 2003 Jun; 22(26):4102-10. PubMed ID: 12821944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic myelogenous leukemia as a paradigm of early cancer and possible curative strategies.
    Clarkson B; Strife A; Wisniewski D; Lambek CL; Liu C
    Leukemia; 2003 Jul; 17(7):1211-62. PubMed ID: 12835715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis.
    Koschmieder S; Göttgens B; Zhang P; Iwasaki-Arai J; Akashi K; Kutok JL; Dayaram T; Geary K; Green AR; Tenen DG; Huettner CS
    Blood; 2005 Jan; 105(1):324-34. PubMed ID: 15331442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selection of myeloid progenitors lacking BCR/ABL mRNA in chronic myelogenous leukemia patients after in vitro treatment with the tyrosine kinase inhibitor genistein.
    Carlo-Stella C; Dotti G; Mangoni L; Regazzi E; Garau D; Bonati A; Almici C; Sammarelli G; Savoldo B; Rizzo MT; Rizzoli V
    Blood; 1996 Oct; 88(8):3091-100. PubMed ID: 8874208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BCR-ABL promotes hematopoietic stem and progenitor cell formation in embryonic stem cells.
    Artus J; Zenych A; Simanic I; Desterke C; Clay D; Saïm S; Ijjeh Y; de Souza LEB; Coignard S; Bennaceur-Griscelli A; Turhan AG; Foudi A
    Exp Hematol; 2023 Aug; 124():22-35.e3. PubMed ID: 37331423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid generation of a tetracycline-inducible BCR-ABL defective retrovirus using a single autoregulatory retroviral cassette.
    Dugray A; Geay JF; Foudi A; Bonnet ML; Vainchenker W; Wendling F; Louache F; Turhan AG
    Leukemia; 2001 Oct; 15(10):1658-62. PubMed ID: 11587226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bmi1 reprograms CML B-lymphoid progenitors to become B-ALL-initiating cells.
    Sengupta A; Ficker AM; Dunn SK; Madhu M; Cancelas JA
    Blood; 2012 Jan; 119(2):494-502. PubMed ID: 22101899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of p210(BCR-ABL) activity in transduced primary human hematopoietic cells controls lineage programming.
    Chalandon Y; Jiang X; Hazlewood G; Loutet S; Conneally E; Eaves A; Eaves C
    Blood; 2002 May; 99(9):3197-204. PubMed ID: 11964283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells.
    Zhou LL; Zhao Y; Ringrose A; DeGeer D; Kennah E; Lin AE; Sheng G; Li XJ; Turhan A; Jiang X
    J Exp Med; 2008 Oct; 205(11):2657-71. PubMed ID: 18936234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic myelogenous leukemia: molecular and cellular aspects.
    Pasternak G; Hochhaus A; Schultheis B; Hehlmann R
    J Cancer Res Clin Oncol; 1998; 124(12):643-60. PubMed ID: 9879825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. c-kit ligand stimulates tyrosine phosphorylation of a similar pattern of phosphotyrosyl proteins in primary primitive normal hematopoietic progenitors that are constitutively phosphorylated in comparable primitive progenitors in chronic phase chronic myelogenous leukemia.
    Wisniewski D; Strife A; Berman E; Clarkson B
    Leukemia; 1996 Feb; 10(2):229-37. PubMed ID: 8637231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Favorable therapeutic index of a p210(BCR-ABL)-specific tyrosine kinase inhibitor; activity on lineage-committed and primitive chronic myelogenous leukemia progenitors.
    Kasper B; Fruehauf S; Schiedlmeier B; Buchdunger E; Ho AD; Zeller WJ
    Cancer Chemother Pharmacol; 1999; 44(5):433-8. PubMed ID: 10501919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of the c-jun gene in p210 BCR-ABL transformed cells corresponds with activity of JNK, the c-jun N-terminal kinase.
    Burgess GS; Williamson EA; Cripe LD; Litz-Jackson S; Bhatt JA; Stanley K; Stewart MJ; Kraft AS; Nakshatri H; Boswell HS
    Blood; 1998 Oct; 92(7):2450-60. PubMed ID: 9746785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absence of the transcription factor CCAAT enhancer binding protein alpha results in loss of myeloid identity in bcr/abl-induced malignancy.
    Wagner K; Zhang P; Rosenbauer F; Drescher B; Kobayashi S; Radomska HS; Kutok JL; Gilliland DG; Krauter J; Tenen DG
    Proc Natl Acad Sci U S A; 2006 Apr; 103(16):6338-43. PubMed ID: 16606850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.